TG Therapeutics Inc (TGTX)
16.31
-0.58
(-3.43%)
USD |
NASDAQ |
May 31, 16:00
16.29
-0.02
(-0.12%)
After-Hours: 20:00
TG Therapeutics Cash from Financing (TTM): 47.48M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 47.48M |
December 31, 2023 | 72.70M |
September 30, 2023 | 72.76M |
June 30, 2023 | 72.61M |
March 31, 2023 | 25.70M |
December 31, 2022 | -0.391M |
September 30, 2022 | 55.56M |
June 30, 2022 | 47.92M |
March 31, 2022 | 40.62M |
December 31, 2021 | 41.42M |
September 30, 2021 | 388.81M |
June 30, 2021 | 431.44M |
March 31, 2021 | 679.69M |
December 31, 2020 | 679.83M |
September 30, 2020 | 374.79M |
June 30, 2020 | 360.22M |
March 31, 2020 | 147.41M |
December 31, 2019 | 204.21M |
September 30, 2019 | 110.55M |
June 30, 2019 | 94.35M |
March 31, 2019 | 118.09M |
December 31, 2018 | 113.64M |
September 30, 2018 | 123.68M |
June 30, 2018 | 147.41M |
March 31, 2018 | 99.18M |
Date | Value |
---|---|
December 31, 2017 | 133.66M |
September 30, 2017 | 120.34M |
June 30, 2017 | 92.17M |
March 31, 2017 | 91.91M |
December 31, 2016 | 5.016M |
September 30, 2016 | 3.617M |
June 30, 2016 | 19.32M |
March 31, 2016 | 33.41M |
December 31, 2015 | 68.72M |
September 30, 2015 | 95.43M |
June 30, 2015 | 103.89M |
March 31, 2015 | 86.53M |
December 31, 2014 | 68.64M |
September 30, 2014 | 41.96M |
June 30, 2014 | 55.69M |
March 31, 2014 | 56.20M |
December 31, 2013 | 39.69M |
September 30, 2013 | 39.56M |
June 30, 2013 | 1.639M |
March 31, 2013 | 0.7969M |
December 31, 2012 | 11.90M |
September 30, 2012 | 21.78M |
June 30, 2012 | 21.81M |
March 31, 2012 | 0.00 |
December 31, 2011 | 9.825M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.391M
Minimum
Dec 2022
679.83M
Maximum
Dec 2020
197.38M
Average
83.55M
Median
Cash from Financing (TTM) Benchmarks
Amicus Therapeutics Inc | 56.19M |
Alnylam Pharmaceuticals Inc | 154.67M |
Cytokinetics Inc | 332.28M |
Insmed Inc | 171.86M |
Madrigal Pharmaceuticals Inc | 1.116B |